Bausch + Lomb advances dual-action dry eye drop into Phase 3 after Phase 2 Day 15 endpoint win
BLCO•BL1332 shows positive Phase 1b data
BL1332, a topical ocular pain candidate, delivered positive Phase 1b data that backed its mechanism, supporting continued development.
Topline Phase 2 results in post-surgical pain are expected within the next few months; peak sales estimates are about $700 million and $1.4 billion.
Dual-action dry eye drop moves into Phase 3
Bausch + Lomb advanced two first-in-class eye therapies into new trials following clinical readouts already released.
A dual-action dry-eye drop posted encouraging mid-stage results, supporting a move into Phase 3 with an earlier primary assessment.
The study missed its main endpoint at the original timepoint, but secondary findings supported a clinically meaningful benefit versus lifitegrast alone.
